SEROCONVERSION TO HBV ASSOCIATED WITH SEROCONVERSION TO HIV IN A COHORT OF INTRAVENOUS DRUG MISUSERS IN TURIN, ITALY

Citation
A. Sinicco et al., SEROCONVERSION TO HBV ASSOCIATED WITH SEROCONVERSION TO HIV IN A COHORT OF INTRAVENOUS DRUG MISUSERS IN TURIN, ITALY, European journal of epidemiology, 11(5), 1995, pp. 535-539
Citations number
NO
Categorie Soggetti
Public, Environmental & Occupation Heath
ISSN journal
03932990
Volume
11
Issue
5
Year of publication
1995
Pages
535 - 539
Database
ISI
SICI code
0393-2990(1995)11:5<535:STHAWS>2.0.ZU;2-8
Abstract
Between March 1986 and March 1994, the seroconversion to HBV associate d to the seroconversion to HIV was investigated in 120 HIV seroconvert ers drawn from 2368 i.v. drug misusers screened for HIV, HBV and STDs. Among the 185 individuals susceptible to HIV and HBV at intake (41/12 0 HIV seroconverters and 144/364 HIV-negative controls), HBV seroconve rsion was associated with the seroconversion to HIV (p = 0.006) and hi story of more than 3 sexual partners per year (p = 0.000). Only the hi story of more than 3 partners per year remained associated with the HB V seroconversion in the conditional regression. The associated serocon version to HIV and HBV was linked to the short period of i.v. drug inj ections (p = 0.032), history of more than 3 partners per year (p = 0.0 00) and more than 3 i.v. drug injections per day (p = 0.016). Compared to the seroconverters to HBV alone, the seroconverters to HBV and HIV were likely to have higher frequency of i.v. drug injection per day o n univariate (p = 0.031) and multivariate analysis (p = 0.024). The se roconverters to both the viruses differed from the seroconverters to H IV alone in the year of drug debut (p = 0.045), short period of i.v. d rug use (p = 0.048) and high frequency of injection per day (p = 0.008 ). The multivariate analysis confirmed only the association with high frequency of injection per day (p = 0.033). Higher risk of HIV serocon version from the debut of i.v. drug use was observed in the subjects w ith concurrent HBV seroconversion (Log-Rank test: p = 0.0008).